City
Epaper

Adar Poonawalla says Serum Institute stopped Covishield production in Dec 2021

By Lokmat English Desk | Published: October 20, 2022 8:04 PM

The Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla said that vaccine manufacturer stopped the production ...

Open in App

The Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla said that vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired.

Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers Network (DCVMN), he said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic, PTI reported.

According to the Serum CEO, booster vaccines have no demand because of the "general lethargy among people and also because they are fed up with the pandemic." Boosters have no demand at the moment. There is lethargy generally. People are fed up of COVID, vaccines. To be honest, I am also fed up with it. We all are, he further stated.

 

Tags: Adar poonawalaSerum Institute Of IndiaCovishield
Open in App

Related Stories

HealthAfter Covishield, BHU Study Reveals Side Effects of Covaxin; Including Hair Loss, Skin Issues, and Menstrual Irregularities

InternationalAstraZeneca Withdraws COVID-19 Vaccine Globally Days After Side Effect Row, Firm Says Decision ‘Commercial’

NationalCovaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine, Says ‘Safety Is Primary Focus for All Our Vaccines’

NationalAkhilesh Yadav Attacks BJP on Issue of Covishield Vaccine Side Effect, Says 'People Who Got Injection Will Vote Against Party'

NationalCovishield Vaccine Side Effect: Serum Institute Faces Legal Action As Parents of Deceased Girls Prepare Lawsuit

Health Realted Stories

Health1 in 3 people die of heart disease due to buildup of fats, cholesterol

HealthCovaxin shows excellent safety track record: Bharat Biotech on study citing risks

Health50 pc high BP patients may suffer from kidney damage: Doctors

HealthKozhikode Medical College Hospital orders probe into 4-year-old's surgery goof-up

HealthStudy reveals how infertility treatment can double risk of postpartum heart disease